( CNN ) The leading vaccines for Ebola will soon be tested in healthy volunteers in Africa , according to the World Health Organization . At a press conference Friday , Marie-Paule Kieny , who leads the WHO Ebola vaccine work , suggested there has been real promise offered from initial tests of two of the vaccines being studied . One comes from Merck and NewLink and the other is licensed by GlaxoSmithKline . Both vaccines have `` an acceptable safety profile '' meaning there are no adverse affects that would keep it from being tested in a broader population . Trials of the vaccines in Africa should start soon . Health care workers will be among some of the first volunteers to be a part of this next stage of the test . Earlier the trial of the vaccine made by Merck and NewLink were stopped in December after some of the volunteers in the trial had `` transient mild '' joint pain . After investigating that side effect , scientists concluded it was not a big enough issue to stop the development of the vaccine . No similar side effects were noted in the other vaccine trial . There are other Ebola vaccines being tested by companies in the United States and in Russia . While the Ebola epidemic seems to be slowing , people are still dying infections continue . To date , there have been 19,340 cases with 7,518 deaths in the countries most impacted by the epidemic , according to the latest WHO report .
Leading vaccines for Ebola also show early promise . Tests of the new vaccines should soon begin in healthy populations in Africa . There have been 800 cases with 7,518 deaths so far in the countries most impacted by the epidemic according to WHO report .